StemEx (carlecortemcel-L) / Ayrmid - LARVOL DELTA

Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. (PubMed, Biol Blood Marrow Transplant) - P2/3; "In this multi-national comparative study, transplanting expanded CD34+ stem cells from a portion of a single UCB unit, with the remaining un-manipulated fraction improved 100 day survival compared to DUCBT controls while facilitating myeloid and platelet engraftment. This trial was registered at www.clinicaltrials.gov as #NCT00469729."

Journal

ACUTE GRAFT VERSUS HOST DISEASE (GVHD), CHRONIC GVHD AND NON-RELAPSE MORTALITY (NRM) ASSOCIATED WITH MISMATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)- A SYSTEMATIC REVIEW (ISPOR 2019) - "The incidence of grade III-IV acute GVHD events was 10.0% among patients receiving UM171-expanded umbilical cord blood (UCB) grafts, 12.2% with NiCord®-expanded-UCB, 19.4% with StemEx®-expanded-UCB and ranged from 3.2-21.2% with other mismatched allo-HSCT (majority mixed bone marrow/peripheral blood). Patients treated with UM171-expanded-UCB grafts experienced the lowest rates of NRM and moderate-severe chronic GHVD at 24 months relative to UCB and other mismatched graft sources identified in the SLR. Additionally, rates of grade III-IV acute GVHD were lower in UM171-expanded-UCB grafts compared to most, but not all, other sources identified."

Review